AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00692198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen therapy
Description: Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
Study NCT01795534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot shot then placebo shot
Description: Beetroot shot, four day wash out, then placebo shot
Study NCT01795534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo shot then beetroot shot
Description: Placebo shot, four day wash out, then beetroot shot
Study NCT01737203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra
Description: 50 mg tablet on Day 1 of each period
Study NCT01737203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil ODT
Description: 50 mg tablet on Day 1 of each period
Study NCT04392791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balneotherapy
Description: Balneotherapy, a medical remedy, with medically and legally recognized mineral waters for therapeutic and rehabilitation purposes
Study NCT04647175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fermented aronia
Description: Given twice daily for 8 weeks
Study NCT04647175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aronia
Description: Given twice daily for 8 weeks
Study NCT01186991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onartuzumab Placebo
Description: Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
Study NCT03828617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20vPnC
Study NCT03828617 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine
Study NCT04616859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol and Energy Drink (AmED)
Description: Multiple oral dose of alcohol mixed with ED
Study NCT04616859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol and Energy drink Placebo
Description: Multiple oral dose of alcohol mixed with ED placebo (soft drink)
Study NCT04616859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol placebo and Energy drink
Description: Multiple oral dose of alcohol placebo (water) mixed with ED
Study NCT04616859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol placebo and energy drink placebo
Description: Multiple oral dose of alcohol placebo (water) mixed with ED placebo (soft drink)
Study NCT04338308 — intervention group
Intervention type: DEVICE
Intervention: new-DES
Description: with ot without embolic protection device
Study NCT04338308 — intervention group
Intervention type: DEVICE
Intervention: BMS
Description: with ot without embolic protection device
Study NCT01512095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
Study NCT01512095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
Study NCT02259465 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: low FODMAP diet
Description: Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
Study NCT02259465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low FODMAP diet
Description: Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
Study NCT02259465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligofructose
Description: Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
Study NCT02259465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
Study NCT01530464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline plus ambrisentan
Description: Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0070-0002-0349
Description: Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
Study NCT04590625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
Study NCT04590625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
Study NCT04590625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis Platinum
Description: cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
Study NCT04590625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
Study NCT04647175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Given twice daily for 8 weeks
Study NCT04311489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ularitide
Description: Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.
Study NCT04311489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.
Study NCT02327702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients at baseline till 48 weeks after delivery
Study NCT04320433 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
Study NCT02368288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
Study NCT01736722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visualase®
Description: The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
Study NCT04099797 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: C7R-GD2.CART cells (IV and ICV infusion)
Description: Dose levels administered are by IV infusion followed by ICV infusion.~Cycle 1: 10 million cells/m2 delivered IV with lymphodepletion.~Cycle 2 (and subsequent cycles):~Dose level 1: 2 million cells ICV with lymphodepletion. Dose level 2: 5 million cells ICV with lymphodepletion.
Study NCT04099797 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: C7R-GD2.CAR T cells (IV infusion)
Description: Dose levels administered are by IV infusion. For all cycles, the dose level is 10 million cells/m2 IV with lymphodepletion.
Study NCT01702025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Yellow corn meal in gel capsules
Study NCT01702025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: National Drug Code (NDC) 0143-1020-01
Study NCT02625636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR438544
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02625636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT02625636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-glucagon
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT00296686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
Study NCT00296686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
Study NCT00296686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triiodothyronine
Description: For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
Study NCT01014013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem sodium (MK0826)
Description: a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
Study NCT01014013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ceftriaxone sodium
Description: a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
Study NCT01702025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methazolamide
Description: NDC 0781-1072-01
Study NCT04209426 — intervention group
Intervention type: DEVICE
Intervention: THA with SYMBOL CUP DMR HA
Study NCT04209426 — intervention group
Intervention type: DEVICE
Intervention: THA with SYMBOL CUP DM CEM
Study NCT02396524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hockey FIT Program
Description: Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
Study NCT00931866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Topical diclofenac patch applied once daily to area of pain
Study NCT00931866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Patch
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
Study NCT00728455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
Study NCT01059461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin®
Description: injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
Study NCT02729298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-0903
Description: Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
Study NCT02920866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Strength Integration (FSI)
Description: FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
Study NCT02920866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CON)
Description: Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
Study NCT02900508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming training
Study NCT02900508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy intervention
Study NCT02010671 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey
Study NCT01702025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline+Methazolamide
Description: NDC 0143-1020-01 and NDC 0781-1072-01
Study NCT00704938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
Study NCT00704938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes
Description: Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10\^8 cells to 5 x 10\^10 cells.
Study NCT00704938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-adenovirus p53 vaccine
Description: Ad-p53 DC vaccine, up to 2 x 10\^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
Study NCT00704938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
Study NCT00704938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60mg/kg/day (Days-7,-6)
Study NCT00704938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25mg/m\^2 (Days -5, -4, -3, -2, and -1)
Study NCT04021888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
Study NCT04021888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
Study NCT02492373 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: topical 0.05% Clobetasol propionate ointment
Description: Apply only on the treated area twice a day as mentions
Study NCT02492373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical 0.05% Clobetasol propionate ointment
Description: Apply only on the treated area twice a day as mentions
Study NCT02492373 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Q switched Nd:YAG laser 532 nm
Description: Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
Study NCT02492373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q switched Nd:YAG laser 532 nm
Description: Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
Study NCT03410563 — intervention group
Intervention type: BEHAVIORAL
Intervention: Auditory inputs
Description: Three different auditory inputs
Study NCT00659932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Cognitive behavioural therapy (CBT)
Description: The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
Study NCT00659932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed CBT
Description: Commencement of the CBT Group Program is delayed 3 months
Study NCT01293825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone
Description: Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the offending agent. Study psychiatrist will switch the offending agent to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone.
Study NCT01209351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00616850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous femoral catheter block
Description: A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.